Published in Nat Rev Neurol on June 15, 2010
Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice. J Clin Invest (2011) 2.23
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A (2012) 1.40
FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. PLoS One (2011) 1.07
Astrocyte-derived BDNF supports myelin protein synthesis after cuprizone-induced demyelination. J Neurosci (2014) 1.04
S1P is associated with protection in human and experimental cerebral malaria. Mol Med (2011) 1.02
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune Dis (2012) 0.93
Topographical and biological evidence revealed FTY720-mediated anergy-polarization of mouse bone marrow-derived dendritic cells in vitro. PLoS One (2012) 0.90
Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Ann Clin Transl Neurol (2014) 0.87
Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol (2016) 0.86
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther (2014) 0.85
Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice. NMR Biomed (2013) 0.85
FTY720, a sphingosine-1 phosphate receptor modulator, improves liver fibrosis in a mouse model by impairing the motility of bone marrow-derived mesenchymal stem cells. Inflammation (2014) 0.84
Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study. Neurol Clin Pract (2012) 0.84
FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons. PLoS One (2013) 0.83
Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. Ther Clin Risk Manag (2016) 0.82
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr (2012) 0.82
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol (2013) 0.81
The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination. Br J Pharmacol (2014) 0.81
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. J Neuroinflammation (2014) 0.80
Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets. Transl Stroke Res (2016) 0.80
Inhibition of de novo ceramide biosynthesis by FTY720 protects rat retina from light-induced degeneration. J Lipid Res (2013) 0.79
Sphingosine-1-Phosphate Receptor Antagonism Enhances Proliferation and Migration of Engrafted Neural Progenitor Cells in a Model of Viral-Induced Demyelination. Am J Pathol (2015) 0.79
Sphingolipids Are Dual Specific Drug Targets for the Management of Pulmonary Infections: Perspective. Front Immunol (2017) 0.79
Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke. Front Neurol (2016) 0.78
The immune system in Duchenne muscular dystrophy: Friend or foe. Rare Dis (2015) 0.78
Potential of urinary metabolites for diagnosing multiple sclerosis. ACS Chem Biol (2013) 0.78
Chronic myeloid leukemia: the basis of treatment for tomorrow. Haematologica (2011) 0.78
The sphingosine-1-phosphate analogue, FTY-720, promotes the proliferation of embryonic neural stem cells, enhances hippocampal neurogenesis and learning and memory abilities in adult mice. Br J Pharmacol (2016) 0.78
Antidepressant activity of fingolimod in mice. Pharmacol Res Perspect (2015) 0.78
1,25-Dihydroxyvitamin D3-Conditioned CD11c+ Dendritic Cells are Effective Initiators of CNS Autoimmune Disease. Front Immunol (2015) 0.77
Vagomimetic effects of fingolimod: physiology and clinical implications. CNS Neurosci Ther (2014) 0.77
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2011) 0.77
Usage of sphingosine kinase isoforms in mast cells is species and/or cell type determined. J Immunol (2013) 0.76
Sphingolipid profile alters in retinal dystrophic P23H-1 rats and systemic FTY720 can delay retinal degeneration. J Lipid Res (2016) 0.76
Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patients. J Cent Nerv Syst Dis (2011) 0.75
Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection"). Neurotherapeutics (2015) 0.75
The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis. PLoS One (2016) 0.75
Where are we going with CML research? Leuk Suppl (2012) 0.75
Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices. Curr Neurol Neurosci Rep (2016) 0.75
Pleiotropic effects of sphingosine-1-phosphate signaling to control human chorionic mesenchymal stem cell physiology. Cell Death Dis (2017) 0.75
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med (2010) 13.70
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature (2004) 12.72
Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol (2003) 9.29
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (2002) 8.63
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci (2009) 7.15
The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem (2002) 6.96
Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med (2006) 6.60
Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science (2005) 5.50
Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci (2006) 4.90
Autoimmune T cell responses in the central nervous system. Nat Rev Immunol (2009) 4.73
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med (2005) 4.67
Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol (2007) 4.42
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol (1981) 3.96
"Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev (2008) 3.80
Lysophospholipid receptors: signaling and biology. Annu Rev Biochem (2004) 3.78
Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol (2004) 3.65
Active induction of experimental allergic encephalomyelitis. Nat Protoc (2006) 3.64
Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol (2007) 3.63
Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol (2005) 3.59
Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem (2004) 3.57
Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther (2007) 3.45
The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol (2008) 3.35
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature (2009) 3.33
Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature (2009) 2.79
International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev (2002) 2.75
The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol (2009) 2.73
Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol (2008) 2.71
FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant (2004) 2.70
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol (2009) 2.49
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol (2009) 2.47
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc Natl Acad Sci U S A (2002) 2.10
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med (2006) 2.01
Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron (2005) 2.01
Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol (2007) 2.00
Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) (1994) 1.93
Sphingosine-1-phosphate rapidly induces Rho-dependent neurite retraction: action through a specific cell surface receptor. EMBO J (1996) 1.90
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther (2007) 1.88
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Lysophospholipid receptors. Annu Rev Pharmacol Toxicol (2001) 1.75
FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol (2005) 1.74
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther (2003) 1.73
Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging (2004) 1.72
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol (2002) 1.71
Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem (2006) 1.63
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol (2005) 1.63
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol (2006) 1.56
FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol (2008) 1.55
The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol Chem (2005) 1.49
FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol (2008) 1.45
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42
Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem (2004) 1.41
Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J Neurosci (1997) 1.40
Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther (2007) 1.40
The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther (2007) 1.40
Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells (2006) 1.38
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol (2004) 1.37
Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med (2009) 1.34
Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem (2007) 1.30
Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci (2008) 1.29
Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology (2007) 1.29
Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med (2009) 1.27
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull (2007) 1.26
Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol (2009) 1.26
Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med (2010) 1.21
Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia (2007) 1.16
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol (2009) 1.15
Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J (2007) 1.13
CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med (2001) 1.13
Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol (2004) 1.10
Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch Ophthalmol (2008) 1.09
Neuronal damage in brain inflammation. Arch Neurol (2007) 1.07
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci (2010) 1.07
S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur J Neurosci (2006) 1.07
Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am J Pathol (2008) 1.05
S1P3 confers differential S1P-induced migration by autoreactive and non-autoreactive immature B cells and is required for normal B-cell development. Eur J Immunol (2010) 1.04
FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res (2010) 1.02
Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur J Neurosci (2001) 1.01
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem (2009) 0.95
Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology (2009) 0.94
Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis? Brain (2008) 0.89
Sphingosine-1-phosphate induces apoptosis of cultured hippocampal neurons that requires protein phosphatases and activator protein-1 complexes. Neuroscience (1999) 0.88
Development of oral cladribine for the treatment of multiple sclerosis. J Neurol (2010) 0.86
EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol (2006) 0.84
p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. Proc Natl Acad Sci U S A (2009) 0.84
EDG receptors as a therapeutic target in the nervous system. Ann N Y Acad Sci (2000) 0.83
Lysophospholipid receptors are differentially expressed in rat terminal Schwann cells, as revealed by a single cell rt-PCR and in situ hybridization. Acta Histochem Cytochem (2006) 0.82
Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann Neurol (2009) 0.81
Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J Clin Pharmacol (2006) 0.76
Oral therapies for multiple sclerosis: are we there yet? Lancet Neurol (2010) 0.76
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Guillain-Barré syndrome. N Engl J Med (2012) 6.28
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol (2010) 3.26
Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet (2003) 3.22
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis (2010) 2.32
New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci (2002) 2.21
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood (2008) 2.01
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 1.92
Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol (2012) 1.84
Chronic inflammatory demyelinating polyneuropathy. N Engl J Med (2005) 1.79
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med (2016) 1.73
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci (2003) 1.65
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology (2013) 1.56
Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol (2006) 1.54
Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol (2003) 1.48
Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation (2012) 1.47
Towards individualised multiple-sclerosis therapy. Lancet Neurol (2005) 1.46
Neuromyelitis optica following human papillomavirus vaccination. Neurology (2012) 1.44
Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol (2009) 1.42
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother (2012) 1.40
Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol (2005) 1.40
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol (2003) 1.39
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol (2007) 1.34
Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler (2013) 1.30
Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol (2009) 1.28
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. Ann Neurol (2005) 1.25
Enhancing remyelination in disease--can we wrap it up? Brain (2011) 1.25
Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs (2008) 1.25
Optical coherence tomography in parkinsonian syndromes. PLoS One (2012) 1.24
In vivo MRI of brain inflammation in human ischaemic stroke. Brain (2004) 1.24
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Cerebrospinal fluid of brain trauma patients inhibits in vitro neuronal network function via NMDA receptors. Ann Neurol (2009) 1.24
Animal models of multiple sclerosis--potentials and limitations. Prog Neurobiol (2010) 1.23
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: a review. Arch Neurol (2003) 1.22
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22
The complex world of oligodendroglial differentiation inhibitors. Ann Neurol (2011) 1.19
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol (2006) 1.17
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol (2009) 1.15
From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol (2007) 1.14
CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. J Cell Sci (2010) 1.13
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol (2005) 1.13
Gene expression profiling reveals that peripheral nerve regeneration is a consequence of both novel injury-dependent and reactivated developmental processes. J Neurochem (2006) 1.12
Remyelinating strategies for the treatment of multiple sclerosis. Prog Neurobiol (2002) 1.12
Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2009) 1.12
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol (2005) 1.10
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09
Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. Brain (2006) 1.09
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve (2004) 1.09
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler (2012) 1.09
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain (2002) 1.08
Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol (2007) 1.08
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci (2010) 1.07
Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve (2013) 1.06
Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol (2011) 1.06
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler (2012) 1.04
Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol (2013) 1.04
Immune circuitry in the peripheral nervous system. Curr Opin Neurol (2006) 1.03
Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke. Stroke (2007) 1.03
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol (2011) 1.02
Development and pharmacological modulation of embryonic stem cell-derived neuronal network activity. Exp Neurol (2007) 1.02
Current disease-modifying therapies in multiple sclerosis. Semin Neurol (2003) 1.01
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol (2007) 1.01
Statins--a cure-all for the brain? Nat Rev Neurosci (2005) 1.00
Activation of CXCR7 receptor promotes oligodendroglial cell maturation. Ann Neurol (2010) 0.99